Dr Carter joins VLST from Seattle Genetics, where he led antibody technologies since 2003 including as vice president, since 2004. Prior to that, Dr Carter was director of research for antibody technologies at Amgen.
Dr Carter received a BA in natural sciences from Cambridge University in 1982 and a PhD in 1986 under Greg Winter at the MRC Laboratory of Molecular Biology in Cambridge.
Martin Simonetti, president and CEO of VLST, said: “Paul is an extremely experienced leader in antibody research and has been a significant contributor to the development of drug pipelines and therapeutic platform technologies. We are very pleased to have Paul join the VLST team and direct our research efforts toward the rapid advancement of our novel product candidates.”